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ver the last decade, landmark 
clinical trials (summarized in 
Tables 1 and 2) have shown 
that statin therapy reduces coronary 
events in patients with or without 
prior cardiovascular disease [1–12]. 
More recent studies, summarized in 
Table 3, show that the larger the statin 
dosage, the greater the reduction in 
cardiovascular clinical events [13–17]. 
A meta-analysis involving 90,056 
patients in 14 randomized trials 
emphasizes that the beneﬁ  t of statin 
treatment is not limited to a reduction 
in coronary disease; treatment also 
reduces the incidence of strokes, 
coronary revascularization, and 
coronary and total mortality [18].
    But statins are expensive, and 
clinicians and policymakers must 
objectively review the literature so that 
statin therapy can be appropriately 
initiated and be cost effective. In 
developing countries, where a changing 
lifestyle is increasing the incidence of 
cardiovascular disease, the need to be 
cost effective is even more pressing. 
This paper attempts to derive a fair and 
evidence-based answer to four practical 
questions that are especially relevant in 
less wealthy societies: (1) In whom and 
when should statin therapy be initiated? 
(2) What lipid level should physicians 
aim for? (3) Do different ethnic groups 
respond differently to statins? and (4) 
Are statins cost effective?
    In Whom and When Should Statins 
Be Initiated?
    Statins should no longer be seen 
as treatment for hyperlipidemia, 
but should be viewed as treatment 
to reduce and prevent clinical 
cardiovascular events. Thus, those 
requiring statins are those at high risk 
of cardiovascular events, regardless of 
the baseline lipid levels. In assessing the 
cardiovascular risk of the presenting 
patient, lipid levels form only one of 
the many clinical parameters to be 
taken into consideration [19–21]. 
    A strategy of treatment based on 
risk will ensure that patients likely to 
suffer from cardiovascular outcomes 
will be treated regardless of their initial 
lipid level, and will avoid unnecessary 
treatment of the low-risk patient with 
hyperlipidemia who may not beneﬁ  t 
from therapy. The use of lipid level 
to decide the initiation of treatment 
must be replaced by the question, “At 
what cardiovascular risk should statins 
be started?” Similarly, the individual 
patient’s risk of possible adverse 
consequences of treatment (hepatitis, 
myositis, mood changes) should also 
dictate how cautious the physician 
should be in initiating and increasing 
statin usage.
    What Target Lipid Level Should 
You Aim For?
    None of the clinical trials discussed 
above were designed to answer the 
question of what lipid level doctors 
should aim for when prescribing statins 
to lower a patient’s cardiovascular risk. 
In contrast, other studies, such as the 
UK Prospective Diabetes Study Group 
study and the Hypertension Optimal 
Treatment study, were speciﬁ  cally 
designed to determine target levels for 
reduction of risk factors (such as blood 
pressure and blood glucose) [22–24].
    Based on a post-hoc review of 
the major statin trials, the Adult 
Treatment Panel III of the US National 
Cholesterol Education Program 
recently concluded: “In high-risk 
persons, the recommended low-density 
lipoprotein cholesterol (LDL-C) goal 
is < 100 mg/dl, but when risk is very 
high, an LDL-C goal of < 70 mg/dl is a 
therapeutic option” [25]. This recent 
advice to seek very low lipid levels 
of below 70 mg/dl (1.8 mmol/l) for 
those at especially high risk is thus an 
extrapolation of the studies, and of 
epidemiological data, rather than an 
evidence-based conclusion derived 
from the trials [25,26]. 
    The larger the LDL-C reduction, the 
larger the reduction in vascular disease 
risk, with a reduction of 1 mmol/l 
of LDL-C over ﬁ  ve years reducing 
major vascular events by 23% [18]. 
Accordingly, a higher dose of statin 
will lead to a greater reduction in 
cardiovascular events. However, there 
is an increased incidence of adverse 
effects with higher doses of statins 
[13–17]. Thus, the higher-dose statin 
regime should be reserved for patients 
at especially high risk of cardiovascular 
events. The higher the presenting lipid 
level, the more likely it is that a higher 
dose of statin can be used. 
    In any patient, reaching an LDL-
C level of 70 mg/dl (1.8 mmol/l) 
indicates the level at which the 
statin dosage should not be further 
increased. The onset of clinical or 
biochemical adverse effects, or of 
ﬁ  nancial strain upon patients who 
are having to purchase drugs out of 
pocket, would similarly suggest that 
the upper limit of statin dose has 
been reached. Such an individualized 
approach to statin therapy reinforces 
the need for the physician to manage 
the whole patient clinically, rather 
than to be excessively distracted by 
any arbitrarily deﬁ  ned laboratory lipid 
levels.
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    Are There Ethnic Differences 
in Response to Statins?
    The landmark statin trials were 
conducted in the Western world, 
and ethnic minorities were greatly 
underrepresented [27,28]. However, 
the available data suggest that 
the correlation between elevated 
cholesterol and coronary disease holds 
true for all ethnic groups, including 
Asians and eastern Europeans 
[29–32]. As people in developing 
societies attain a more afﬂ  uent 
lifestyle and change their dietary 
habits accordingly, the incidence of 
dyslipidemia and coronary disease 
both rise signiﬁ  cantly [33,34]. Having 
said this, the Framingham risk table 
may not accurately estimate coronary 
risk amongst Asian patients, and 
may need to be modiﬁ  ed to remain 
relevant for individuals in developing 
societies [35–37]. Trial evidence must 
be adapted to suit local populations. 
    There are ethnic differences in 
response to drug treatment. African-
Americans, for example, are less 
affected by agents targeting the 
renin-angiotensin system than by 
other drugs for treating heart failure 
[38,39]. A Japanese study of 51,321 
patients found that just 5 mg daily of 
simvastatin reduced total cholesterol by 
about 20%, and LDL-C by about 25%; 
these effects persisted for the six years 
of the trial [40]. The US Food and 
Drug Administration notes that serum 
levels of rosuvastatin amongst Asians 
is double that of Caucasians, and has 
advised that rosuvastatin doses should 
be halved in Asian patients [41]. 
    There is a possibility that smaller and 
lighter Asians may only require low-
dose statin therapy, an idea that would 
be most welcome in the poorer parts 
of the world. There are reports that 
low-dose, alternate-day and even weekly 
statin therapy can produce efﬁ  cacious 
and adequate reduction of lipid levels 
[42–45]. Yet studies conducted with 
cerivastatin and simvastatin suggest that 
pharmacokinetic differences between 
different ethnic groups do not require 
clinical dosage modiﬁ  cation [46,47]. 
Ethnic differences in treatment 
response is an area of research that 
governmental bodies must look into, 
given the unwillingness of commercial 
companies to further pursue this route 
of enquiry. 
    Is Statin Therapy Cost-Effective?
    Statin therapy of the appropriately 
high-risk patient has been shown to be 
cost-effective [48–51]. Prevention of 
cardiovascular disease is less expensive 
than the treatment of its clinical 
consequences. However, while curative 
medicine beneﬁ  ts the symptomatic 
and ill patient, preventive medicine 
treats those at risk, who may or may 
not develop the disease in future. 
Thus, practical realities of the local 
community must be remembered when 
considering preventive statin therapy. 
    Developing countries are less afﬂ  uent 
than the industrialized world, and 
funds are needed to combat infectious 
diseases, to provide for maternal and 
child health care, and to develop good 
and clean infrastructure for water and 
food supplies. The nominal per capita 
gross domestic product of Malaysia 
is 12% that of the United States (pp. 
388 and 607 of [52]). In Malaysia, 
treatment for a year with atorvastatin 
(Lipitor) 80 mg daily costs RM3,139, 
which is one sixth of the annual 
Malaysian gross domestic product per 
capita of RM18,734. Thus, only a small 
minority can afford this treatment, 
while the public health system would be 
rapidly bankrupted if it were to provide 
high-dose statin for all patients who 
might beneﬁ  t from it.
    Daily treatment for a year with 
Lipitor (patented atorvastatin) 10 
mg daily costs RM1,606; the same 
treatment with Zocor (patented 
simvastatin) 20 mg daily costs RM1,338; 
treatment with Lescol (patented 
ﬂ  uvastatin) 80 mg daily costs RM1,160; 
treatment with generic simvastatin 20 
mg daily costs RM252; and treatment 
with generic lovastatin daily 40 mg costs 
RM183. Since the trials clearly show 
the beneﬁ  cial effects of simvastatin 
and lovastatin (which are available off 
patent), it is difﬁ  cult to advocate using 
patented statins in the developing 
world [1,5–7]. An alternative strategy 
would be to purchase a high-dose 
formulation of the expensive patented 
statin and break the tablet for daily or 
alternate-day consumption. Breaking 
Lipitor 80 mg into quarters and taking 
it on alternate days, producing an 
effective dose of atorvastatin 10 mg 
daily, costs RM392 annually. The health 
care budget even in the developed 
world is limited, and funds spent 
extravagantly mean that some other 
service would have to be shortchanged. 
  Table 1.   Placebo-Controlled Secondary Prevention Statin Trials   
Variable Scandinavian 
Simvastatin 
Survival Study 
Group [1]
Cholesterol 
and Recurrent 
Events Trial [3]
Long-Term 
Intervention 
with Pravastatin 
in Ischemic Disease 
Study [4]
Heart Protection 
Study Collaborative 
Group [6]
Lescol Intervention 
Prevention Study [8]
Number of patients 4,444 4,159 9,014 20,536 1,677
Duration follow-up (years) 5.4 5 6.1 5 3.9
Statin used Simvastatin, 5 to 40 mg Pra, 40 mg Pra, 40 mg Simvastatin, 40 mg Fluvastatin, 80 mg
Reduction from baseline, 
total cholesterol
25% 20% 18% 20%
Reduction from baseline, LDL-C 35% 28% 25% 29% 22%
Primary end point Total mortality Coronary mortality, 
nonfatal MI
Coronary mortality Total mortality Major adverse cardiac 
events
Relative risk with statin treatment 
(95% conﬁ  dence interval)
0.7 (0.58–0.85) 0.76 (0.64–0.91) 0.76 (0.65–0.88) 0.87 (0.81–0.94) 0.78 (0.69–0.95)
Signiﬁ  cance (  p  value)  p  = 0.0003  p  = 0.003  p  = 0.0001  p  = 0.0003  p  = 0.01
NNT 25 33 53 56 19
    MI, myocardial infarction; pra, pravastatin.
  DOI:  10.1371/journal.pmed.0030050.t001 
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  Discussion
    In objectively reviewing the evidence 
on the statins, it is important not to 
miss the forest for the trees. While 
it is true that some trials of statins 
for reducing cardiovascular disease 
have had negative results (e.g., the 
Antihypertensive and Lipid Lowering 
Treatment to Prevent Heart Attack 
Trial [10], the A to Z trial [14], and 
the trial by the German Diabetes 
and Dialysis Investigators [53]) 
nevertheless a meta-analysis involving 
90,056 patients did ﬁ  nd that statin 
use was associated with a reduction in 
cardiovascular end points [18]. 
    In the Antihypertensive and Lipid 
Lowering Treatment to Prevent Heart 
Attack Trial, in which patients aged 
55 years or older, with an LDL-C 
of 120 to 189 mg/dl (or 100 to 129 
mg/dl if they had known coronary 
heart disease) and triglycerides lower 
than 350 mg/dl, were randomized 
to pravastatin or usual care, 32% of 
usual-care participants with and 29% 
without coronary heart disease started 
taking lipid-lowering drugs. The fact 
that so many usual-care participants 
took lipid-lowering drugs may have 
reduced the apparent beneﬁ  t of the 
statin taken by the treatment group 
[10]. And although the reduction in 
primary end point in the A to Z Trial 
[14] (which compared immediate 
versus delayed treatment with a statin 
after an acute coronary syndrome) did 
not reach statistical signiﬁ  cance, the 
number needed to treat to prevent 
one primary end point (NNT), was 43. 
This was similar to the NNT of 45 in 
the Treating to New Targets Trial (17), 
which produced a highly signiﬁ  cant 
reduction in primary end point (Table 
3). A negative study of statin therapy in 
1,255 patients with diabetes on haemo-
dialysis [53] does not reduce the 
impact of other, larger trials, involving 
a total of more than 100,000 patients 
[18,53,54]. The point that these 
three trials emphasizes is that statin 
treatment should not be blindly started 
for all patients with hyperlipidemia but 
requires a thoughtful assessment of the 
individual patient. 
    There must now be a shift in the 
approach to dyslipidemias. From 
concentrating solely on lipid levels, the 
emphasis is now on risk stratiﬁ  cation, 
since treatment will be most effective 
in patients at high risk of clinical 
cardiovascular disease. The beneﬁ  t of 
statin treatment will thus be greater 
in secondary prevention, where 
patients have preexisting atheromatous 
disease and will be more prone to 
future adverse events. No decision 
can be made on the need for statin 
therapy based solely on lipid levels; all 
therapeutic decisions must be based 
on the risk the patient has for future 
cardiovascular events.
    The recent studies suggest that 
a more aggressive statin treatment 
strategy will lead to greater reductions 
in cardiovascular events. However, the 
incidence of side effects from statin 
treatment, as well as health care costs, 
increases with the increased dose 
used. The most potent of the statins, 
rosuvastatin, is also the one whose 
adverse effects have caused alarm—
some commentators have even called 
for its withdrawal [55–57]. Given the 
need for continuous treatment, the 
ﬁ  nancial burden of patients on high-
dose statins, especially in developing 
countries, may result in reduced 
adherence to treatment.
    Although patients with established 
cardiovascular disease who have initial 
low cholesterol levels have been shown 
to beneﬁ  t from treatment, the question 
of which target level of lipids to aim 
for remains unanswered. The evidence 
is clear that in conventional doses 
studied in the trials, daily simvastatin 
10 to 80 mg, pravastatin 20 to 40 mg, 
atorvastatin 10 to 80 mg, lovastatin 20 
to 40 mg, and ﬂ  uvastatin 80 mg will 
reduce future cardiovascular outcomes. 
Yet hyperlipidemia is not the only risk 
factor predisposing to cardiovascular 
disease, and lowering cholesterol 
cannot be the sole approach to battle 
  Table 2.   Placebo-Controlled Primary Prevention Statin Trials   
Variable West of Scotland 
Coronary 
Prevention Study 
[2]
AFCAPS/TexCAPS 
[5]
Pravastatin in 
Elderly Individuals 
at Risk of Vascular 
Disease [9]
Antihypertensive 
and Lipid Lowering 
Treatment to 
Prevent Heart 
Attack Trial [10]
Anglo-
Scandinavian 
Cardiac Outcomes 
Trial [11]
Collaborative 
Atorvastatin 
Diabetes Study (12]
Number of patients 6,595 6,605 5,804 10,355 10,305 2,838
Duration follow-up 
(years)
4.9 5.2 3.2 4.8 3.3 3.9
Statin used Pra, 40 mg Lovastatin, 20 to 40 mg Pra, 40 mg Pra, 40 mg Ator, 10 mg Ator, 10 mg
Reduction from 
baseline, total 
cholesterol
20% 18% 10%a 24% 26%
Reduction from 
baseline, LDL-C
26% 25% 34% 17%a 35% 40%
Primary end point Nonfatal MI, coronary 
mortality
MI, unstable angina, 
sudden cardiac death
Coronary mortality, 
nonfatal MI, stroke
Total mortality Fatal coronary heart 
disease, nonfatal MI
Acute coronary event, 
Revascularisation, 
stroke
Relative risk with 
statin treatment (95% 
conﬁ  dence interval)
0.69 (0.57–0.83) 0.63 (0.50–0.79) 0.85 (0.74–0.97) 0.99 (0.89–1.11) 0.64 0.63
Signiﬁ  cance (  p  value)  p  < 0.001  p  < 0.001  p  = 0.014  p  = 0.88  p  = 0.0005  p  = 0.001
NNT 42 49 48 250 91 31
  aPatients not on prior statin saw an LDL reduction of 51% and 22% while on atorvastatin and pravastatin 40 mg, respectively. Patients previously on a statin saw further LDL-C reduction of 32% and 0% while on atorvastatin 80 mg and 
pravastatin 40 mg, respectively.
    MI, myocardial infarction; pra, pravastatin; ator, atorvastatin.
  DOI:  10.1371/journal.pmed.0030050.t002 
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this health problem. Treatment of 
other risk factors, such as diabetes 
and hypertension, as well as lifestyle 
changes that include increasing 
physical activity, cessation of smoking, 
and dietary modiﬁ  cation, all have 
an important role to play in the 
prevention of cardiovascular disease 
[58]. No medicine is free of adverse 
effects, and the risk-beneﬁ  t ratio of 
treatment in each patient must be 
carefully considered before initiating 
statin therapy. 
  Conclusion
    When deciding whether or not to 
initiate statin therapy, there should 
be a shift in emphasis away from 
the idea of a “normal lipid proﬁ  le”. 
Instead, the emphasis should be on 
the individual patient and the risk 
factors for cardiovascular disease. The 
actual threshold for therapy varies 
between guidelines but the principle 
remains the same [19–21,35–37]. 
The higher the risk, assessed from 
prior atheromatous disease, diabetes, 
blood pressure, smoking status, age, 
and sex (besides the lipid levels), 
the greater the need to treat and to 
treat aggressively. Indeed, a case can 
be made for all patients with a prior 
atheromatous disease to be on a statin, 
regardless of initial cholesterol level. 
Patients at low risk of cardiovascular 
events should not be treated merely 
because of an abnormal lipid proﬁ  le, 
especially since statin treatment is not 
free from adverse effects. Given the 
ﬁ  nancial costs of statins, it is even more 
  Table 3.   Statin Trials Comparing High-Dose with Low-Dose Regimen   
Variable Pravastatin or Atorvastatin 
Evaluation and Infection 
Therapy [13]
A to Z Trial [14] ALLIANCE Study [16] Treating to New Targetsa 
[17]
Number of patients 4,162 4,497 2,442 10,001
Duration follow-up (years) 2 2 4.5 4.9
Statin used Ator, 80 mg  Pravachol, 40 
mg 
Early intensive 
treatment
Delayed, low-
dose treatment
Ator, 80 mg Usual care Ator, 80 mg Ator, 10 mg
Reduction from baseline, 
total cholesterol
25% 15% 24%  16% Not available Not available
Reduction from baseline, LDL-C 51% (32%)b 22%  (0%) 41% 27% 34% 23% 21%c −3%
Primary end point Cardiovascular event Cardiovascular event Cardiovascular event Cardiovascular event
Relative risk with high dose 
treatment (95% CI)
0.84 (0.74–0.95) 0.89 (0.76–1.04) 0.83 (0.71–0.97) 0.78 (0.69–0.89)
Signiﬁ  cance (  p  value)  p  = 0.005  p  = 0.14  p  = 0.02  p  < 0.001
NNT 26 43 25 45
  aAll patients on atorvastatin 10 mg daily at baseline.
  bPatients not on prior statin saw LDL-C reduction of 51% and 22% while on atorvastatin 80 mg and pravastatin 40 mg, respectively. Patients previously on a statin saw further LDL-C reduction of 32% and 0% while on atorvastatin 80 mg and 
pravastatin 40 mg, respectively.
  cDuring the trial mean reduction in LDL-C of 21% was noted with 80 mg atorvastatin and an increase in LDL-C of 3% was noted on continued 10 mg atorvastatin.
  Ator,  atorvastatin.
  DOI:  10.1371/journal.pmed.0030050.t003 
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